If It Ain’t Broke…: FDA Committee Supports Retaining Soliris REMS
This article was originally published in RPM Report
Executive Summary
FDA’s annual REMS reviews haven’t been the most dramatic advisory committees in recent years. The latest review is the first to involve a major commercial product – Alexion’s Soliris – but also looked at a program that appears successful and non-controversial.
You may also be interested in...
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
The End of the REMS Era? Entyvio Approval Is Another Marker
FDA approved Takeda’s UC and Crohn’s disease therapy without a REMS – even though the product has a theoretical risk of causing PML, based on its similarity to Biogen’s Tysabri.
Class-Wide REMS: "A Self-Propagating Purgatory"
It hasn't been easy for two dozen companies to work together in trying to craft a viable class-wide risk management program for long-acting opioids. If they are successful, expect FDA to push for more class-wide REMS.